Monopar Therapeutics is a biopharmaceutical company focused on developing therapeutics for cancer patients. Co. has compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a mucoadhesive buccal anti-inflammatory tablet for the prevention and treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (5-imino-13-deoxydoxorubicin), a clinical stage topoisomerase II-alpha targeted analog of doxorubicin to retain anticancer activity; and MNPR-101, a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor for the treatment of solid cancers. The MNPR stock yearly return is shown above.
The yearly return on the MNPR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MNPR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|